Crossmark

Systolic Blood Pressure Reduction with Stability as a New Therapeutic Goal in Patients with Intracerebral Hemorrhage: Results of the Pooled Analysis of ATACH 2 and INTERACT 2 Trials

Crossref DOI link: https://doi.org/10.1007/s12028-025-02277-2

Published Online: 2025-05-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Qureshi, Adnan I.

Baskett, William

Martin, Renee H.

Lakhani, Pashmeen

Bhatti, Ibrahim A. https://orcid.org/0009-0003-8579-5593
El Sabae, Hijrah

Al-Mufti, Fawaz

Gomes, Joao A.

Seifi, Ali

Rabinstein, Alejandro A.

Suarez, Jose I.

Steiner, Thorsten

Shyu, Chi-Ren

Anderson, Craig S.
License Information

Text and Data Mining valid from 2025-05-20

Version of Record valid from 2025-05-20
More Information

Article History

Received: 14 November 2024

Accepted: 8 April 2025

First Online: 20 May 2025

Conflicts of interest

: Dr. Qureshi is confounder of Qureshi Medical LLC, QureVasc LLC, and DyQure LLC. Dr. Qureshi also holds a patent on intraarterial sustained release device in the middle meningeal artery.

: The study used publicly available trial data, and consent was not required.

Document is current

Any future updates will be listed below